Microneedles for Drug Delivery via the Gastrointestinal Tract
Name
Langer_Microneedles for drug.pdf
Size
391.91 KB
Format
Adobe PDF
Checksum (MD5)
f529c2083b4fbe0fe3d2a34df25b3e93
Author(s)
Schroeder, Avi
Maa, Ruby C.
Lauwers, Gregory Y.
Polat, Baris E.
Blankschtein, Daniel
Langer, Robert
Traverso, Gio
Schoellhammer, Carl Magnus
Anderson, Daniel Griffith
Date Issued
September 2014
Journal
Journal of Pharmaceutical Sciences
Publisher
Wiley Blackwell
Citation
Traverso, Giovanni, Carl M. Schoellhammer, Avi Schroeder, Ruby Maa, Gregory Y. Lauwers, Baris E. Polat, Daniel G. Anderson, Daniel Blankschtein, and Robert Langer. “Microneedles for Drug Delivery via the Gastrointestinal Tract.” J. Pharm. Sci. (September 2014).
Version
Author's final manuscript
Abstract
Both patients and physicians prefer the oral route of drug delivery. The gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics because of its protease and bacteria-rich environment as well as general pH variability from pH 1 to 7. These extreme environments make oral delivery particularly challenging for the biologic class of therapeutics. Here, we demonstrate proof-of-concept experiments in swine that microneedle-based delivery has the capacity for improved bioavailability of a biologically active macromolecule. Moreover, we show that microneedle-containing devices can be passed and excreted from the GI tract safely. These findings strongly support the success of implementation of microneedle technology for use in the GI tract.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/jps.24182
